Patent ID: 7244558
Filing Date: 2007-07-17
Classification: A61K,A61P,C07K,C12N

Abstract:
1. A vaccine for Newcastle disease comprising a genetically engineered live attenuated Newcastle disease virus, wherein the genetically engineered live attenuated Newcastle disease virus has a F o protein cleavage site having at least two less basic amino acid residues than a F o protein cleavage site of Newcastle disease virus wild type strain Beaudette C, wherein codons of non-basic amino acid residues replacing the at least two basic amino acid residues are different from codons of the basic amino acid residues by at least two nucleotides; and at least one of the features selected from the group consisting of: (1) an amino acid having a non-aromatic side chain at the N terminus of the F 1 cleavage fragment, wherein the amino acid having a nonaromatic side chain is glycine, alanine, valine, leucine or isoleucine; and (2) an open reading frame of a HN glycoprotein being longer than an open reading frame of a HN glycoprotein of Newcastle disease virus wild type strain Beaudette C, wherein the genetically engineered live attenuated Newcastle disease virus is in the form of a vaccine for administration to a subject.